Concepedia

Publication | Closed Access

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

DOI

29

Citations

33

References

2014

Year

L. Rhoda Molife, Emma Dean, Montserrat Blanco-Codesido, Matthew Krebs, André T. Brunetto, Alastair Greystoke, Gennaro Daniele, Lucy Lee, Galina Kuznetsov, Khin Than Myint,
Clinical Cancer Research

Abstract

Golvatinib at the MTD of 400 mg once daily was well tolerated with pharmacodynamic evidence of c-Met target modulation.

References

YearCitations

Page 1